2023年9月8日 · Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

Wide range of targeted sequencing panels for tissue and blood samples, including 3-CE marked NGS-based oncopanels detecting up to ~520 biomarkers, and one FDA Breakthrough Device Designation. QMS supports CLIA/CAP testing, clinical trials under Good Clinical Practice (GCP), and CE-marking product development under Good Manufacturing Practice (GMP).

2023年9月8日 · Burning Rock的最小残留疾病（MRD）产品支持早期非小细胞肺癌癌症治疗的进展，研究结果发表在《癌症细胞》上 Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

2021年10月8日，燃石医学（NASDAQ：BNR）宣布早期非鳞状非小细胞肺癌（Non-Small Cell Lung Cancer，NSCLC）患者术后复发风险精准分层及辅助治疗获益预测方案——朗迪瑞™正式上市。

2022年3月1日，燃石医学（NASDAQ：BNR）宣布，公司自主研发的实体瘤微小残留病灶（Minimal Residual Disease / Molecular Residual Disease, 以下简称“MRD”）检测产品朗微™正式上市。朗微™根据每一位实体瘤患者基因变异图谱，定制个体化的MRD检测方案，可动态评估患 …

Burning Rock’s minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

2024年3月29日 · 燃石医学（伦敦交易所代码/纳斯达克代码：bnr）成立于2014年，公司使命为“用科学守护生命之光”，专注于开发创新可靠、具有临床价值的癌症伴随诊断与早检产品。

2020年11月16日，燃石医学（NASDAQ：BNR）宣布与Myriad Genetics, Inc.（NASDAQ: MYGN, 以下简称“Myriad”）达成独家合作协议，将进行Myriad的核心产品之一——肿瘤同源重组缺陷（homologous recombination deficiency, HRD）检测产品myCh...

GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it will present MRD (molecular residual...

2022年3月15日 · Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it will present MRD (molecular residual disease) clinical data on non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) at the following two sessions of American Association for Cancer Research (AACR) Annual Meeting on April 8, 2022.